secwatch.observer — SEC 8-K summary
======================================

Issuer:     PARDES BIOSCIENCES, INC. (—)
CIK:        0001822711
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001140361-23-041917
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pardes Biosciences acquired by Foresite Capital affiliate for $2.13/share plus CVR; delisted from Nasdaq
--------------------------------------------------------------------------------

- Tender offer expired Aug 30, 2023; 37,836,066 shares (~60.9% of outstanding) validly tendered.
- Shareholders received $2.13 cash per share plus a non-tradeable CVR linked to future monetization of COVID-19 antiviral assets.
- After the tender close, Merger Sub merged with Pardes; company became wholly owned subsidiary of MediPacific (Foresite Capital).
- All shares ceased trading on Nasdaq prior to Aug 31, 2023; deregistration intended.
- Board of directors resigned; new directors from Merger Sub include James B. Tananbaum and Dennis D. Ryan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/brhc20058194_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-041917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer